Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company that combines automation, artificial intelligence, machine learning, and in vivo validation capabilities to discover novel medicines. Its Recursion operating system enables advanced machine learning approaches to reveal drug candidates, mechanisms of action, novel chemistry, and potential toxicity, with the eventual goal of decoding biology and advancing new therapeutics that radically improve people's lives. The company was founded by Blake Borgeson, Christopher C. Gibson, and Dean Y. Li on November 5, 2013 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Successfully navigating the stock market requires patience and a long-term perspective. The key is sticking to a consistent plan and making regular contributions to a retirement account, allowing the power of compounding to work its magic over time.

Is Recursion Pharmaceuticals Stock a Millionaire Maker?

The artificial intelligence (AI) field has been grabbing many headlines on Wall Street in the past two years. Will this trend continue in 2025?

1 Artificial Intelligence (AI) Stock That Could Soar in 2025

Salt Lake City, Utah, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Recursion Pharmaceuticals, Inc. (“Recursion”) (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that on December 19, 2024, the Compensation Committee of Recursion's Board of Directors approved the grant of inducement restricted stock unit (RSU) awards covering 7,952,836 shares of its class A common stock in the aggregate to 230 new employees under Recursion's 2024 Inducement Equity Incentive Plan (the “2024 Plan”). Each award was granted as an inducement material to the employee's commencement of employment with a subsidiary of Recursion in connection with Recursion's acquisition of Exscientia plc and pursuant to Nasdaq Listing Rule 5635(c)(4).

Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing Rules

Recursion Pharmaceuticals leverages AI and machine learning to revolutionize drug discovery, reducing costs and accelerating development, positioning itself as a leader in tech-driven biopharma. The recent acquisition of Exscientia strengthens Recursion's pipeline and partnerships, potentially delivering up to $20 billion in milestone payments from collaborations with pharma giants. Despite unimpressive clinical trial results, the company's innovative platform and strategic partnerships justify a "Buy" rating for long-term, high-risk-tolerant investors.

Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development Platform

SALT LAKE CITY, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) reported initial monotherapy dose-escalation data from the Phase 1/2 study (ELUCIDATE) of REC-617, a selective CDK7 inhibitor, in advanced solid tumors.

Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable Tolerability

Recursion Pharmaceuticals, Inc. expects to meet with the FDA to discuss the potential of advancing REC-994 for the treatment of patients with cerebral cavernous malformation. REC-1245 is a CDK12-adjacent target being developed in a phase 1/2 study for the treatment of patients with biomarker-enriched solid tumors and lymphomas. Data from the phase 1/2 study, exploring the use of REC-1245 for the treatment of patients with biomarker-enriched solid tumors/lymphomas, is expected by the end of 2025 or 1st half of 2026.

Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245

Serve Robotics Inc

NVIDIA Co. NASDAQ: NVDA is the undisputed leader of the artificial intelligence (AI) revolution. The company envisioned an AI future over 12 years ago and began executing the blueprint for domination.

NVIDIA Invested in These 2 AI Stocks, Should You?

Iovance Biotherapeutics

2 Innovative Stocks That Could Deliver Outsize Returns

SALT LAKE CITY, Nov. 20, 2024 (GLOBE NEWSWIRE) -- The business combination of two AI-powered drug discovery and development companies, Recursion (Nasdaq: RXRX) and Exscientia has been completed, with Exscientia becoming a wholly owned subsidiary of Recursion creating a vertically-integrated and technology-enabled drug discovery platform. Exscientia ADSs (Nasdaq: EXAI) ceased trading and will be delisted from Nasdaq.

Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discovery

Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close Update call scheduled for November 20th at 7:30 a.m. Eastern with anticipated close

Recursion and Exscientia Shareholders Approve the Proposed Combination

OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new "gold standard" outperforming CellProfiler OpenPhenom is a non-commercial, publicly available foundation model built on microscopy data that has set the new "gold standard" outperforming CellProfiler

Recursion Announces the Release of OpenPhenom-S/16 in Google Cloud's Model Garden

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.34 per share versus the Zacks Consensus Estimate of a loss of $0.33. This compares to loss of $0.43 per share a year ago.

Recursion Pharmaceuticals (RXRX) Reports Q3 Loss, Misses Revenue Estimates

In an environment where the typical small biotech name is riskier than not, this one is curiously different.

Is Recursion Pharmaceuticals a Millionaire-Maker Stock?

The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $6.40, representing a +1.27% change from its previous close.

Recursion Pharmaceuticals (RXRX) Exceeds Market Returns: Some Facts to Consider

Recursion Pharmaceuticals (RXRX) concluded the recent trading session at $6.68, signifying a -0.89% move from its prior day's close.

Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Company plans to host update call on Nov 20, 2024 after the anticipated close of the proposed business combination with Exscientia Company plans to host update call on Nov 20, 2024 after the anticipated close of the proposed business combination with Exscientia

Recursion to Report Third Quarter 2024 Business Updates and Financial Results on November 6th

This company stands to benefit from a shifting pharmaceutical industry landscape.

3 Key Trends That Are Bullish for Recursion Pharmaceuticals Stock

Recursion Pharmaceuticals (RXRX) reachead $6.36 at the closing of the latest trading day, reflecting a +0.47% change compared to its last close.

Recursion Pharmaceuticals (RXRX) Beats Stock Market Upswing: What Investors Need to Know

SALT LAKE CITY, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Recursion (NASDAQ: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, today announced that the first patient has been dosed in its Phase 2 clinical trial of REC-3964, a potential first-in-class, oral small molecule and new chemical entity for the treatment of recurrent Clostridioides difficile infection. C. diff is a toxin producing bacteria that causes diarrhea and colitis, and can be life threatening. Up to 730,000 cases are estimated to occur in the U.S. and EU5 annually, and the infection is responsible for an estimated 29,000 deaths in the U.S. each year. Recursion's study will initially address the recurrent C. diff. (up to 175,000 cases in the United States per year) population, which costs the healthcare system approximately two billion dollars per year .

Recursion announces first patient dosed in Phase 2 clinical study of REC-3964, a potential first-in-class, oral, non-antibiotic small molecule for recurrent Clostridioides difficile infection

BioAge Labs Inc

Prediction: These 2 Stocks Could Soar in 2025

Wood has a stake in this stock, but it's hardly an "all-in" bet.

Cathie Wood Is Betting on This AI Stock: Is It a Buy?

This clinical-stage drugmaker's AI platform could speed up the development process, but initial results were disappointing.

Down 57% in 2024, Is Recursion Pharmaceuticals a Buy on the Dip?

ExScientia Ltd

NEW YORK, NY / ACCESSWIRE / October 11, 2024 / Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered money for shareholders and is recognized as a Top 50 Firm in the 2018-2022 ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) , relating to its proposed merger with Exscientia PLC.

SHAREHOLDER INVESTIGATION: The M&A Class Action Firm Investigates the Mergers and Imminent Votes of RXRX and EXAI

SoundHound AI Inc

These two AI innovators are reshaping drug discovery and voice technology – find out why Wall Street sees major upside ahead.

2 Artificial Intelligence Stocks That Could Deliver Explosive Gains

Amgen

Biogen

bluebird bio

Bristol-Myers

CRISPR Therapeutics

Editas Medicine

Exact Sciences

Intellia Therapeutics

Pfizer

Kirk Spano and Bhavneesh Sharma talk biotech, pharma, and contrarian buying opportunities. AI is revolutionizing drug discovery by significantly speeding up the process and increasing the probability of successful outcomes, making it a game-changer for the biotech sector.

Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma

News for Recursion Pharmaceuticals Stock (RXRX)